387 related articles for article (PubMed ID: 31483963)
1. Inhaled GM-CSF for Pulmonary Alveolar Proteinosis.
Tazawa R; Ueda T; Abe M; Tatsumi K; Eda R; Kondoh S; Morimoto K; Tanaka T; Yamaguchi E; Takahashi A; Oda M; Ishii H; Izumi S; Sugiyama H; Nakagawa A; Tomii K; Suzuki M; Konno S; Ohkouchi S; Tode N; Handa T; Hirai T; Inoue Y; Arai T; Asakawa K; Sakagami T; Hashimoto A; Tanaka T; Takada T; Mikami A; Kitamura N; Nakata K
N Engl J Med; 2019 Sep; 381(10):923-932. PubMed ID: 31483963
[TBL] [Abstract][Full Text] [Related]
2. Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis.
Trapnell BC; Inoue Y; Bonella F; Morgan C; Jouneau S; Bendstrup E; Campo I; Papiris SA; Yamaguchi E; Cetinkaya E; Ilkovich MM; Kramer MR; Veltkamp M; Kreuter M; Baba T; Ganslandt C; Tarnow I; Waterer G; Jouhikainen T;
N Engl J Med; 2020 Oct; 383(17):1635-1644. PubMed ID: 32897035
[TBL] [Abstract][Full Text] [Related]
3. Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis.
Tazawa R; Trapnell BC; Inoue Y; Arai T; Takada T; Nasuhara Y; Hizawa N; Kasahara Y; Tatsumi K; Hojo M; Ishii H; Yokoba M; Tanaka N; Yamaguchi E; Eda R; Tsuchihashi Y; Morimoto K; Akira M; Terada M; Otsuka J; Ebina M; Kaneko C; Nukiwa T; Krischer JP; Akazawa K; Nakata K
Am J Respir Crit Care Med; 2010 Jun; 181(12):1345-54. PubMed ID: 20167854
[TBL] [Abstract][Full Text] [Related]
4. Direct evidence that GM-CSF inhalation improves lung clearance in pulmonary alveolar proteinosis.
Ohashi K; Sato A; Takada T; Arai T; Nei T; Kasahara Y; Motoi N; Hojo M; Urano S; Ishii H; Yokoba M; Eda R; Nakayama H; Nasuhara Y; Tsuchihashi Y; Kaneko C; Kanazawa H; Ebina M; Yamaguchi E; Kirchner J; Inoue Y; Nakata K; Tazawa R
Respir Med; 2012 Feb; 106(2):284-93. PubMed ID: 22112784
[TBL] [Abstract][Full Text] [Related]
5. Assay system development to measure the concentration of sargramostim with high specificity in patients with autoimmune pulmonary alveolar proteinosis after single-dose inhalation.
Nakano R; Nakagaki K; Itoh Y; Seino U; Ueda T; Tazawa R; Kitamura N; Tanaka T; Nakata K
J Immunol Methods; 2018 Sep; 460():1-9. PubMed ID: 30003894
[TBL] [Abstract][Full Text] [Related]
6. Inhaled granulocyte-macrophage colony stimulating factor for mild-to-moderate autoimmune pulmonary alveolar proteinosis - a six month phase II randomized study with 24 months of follow-up.
Tian X; Yang Y; Chen L; Sui X; Xu W; Li X; Guo X; Liu L; Situ Y; Wang J; Zhao Y; Meng S; Song W; Xiao Y; Xu KF
Orphanet J Rare Dis; 2020 Jul; 15(1):174. PubMed ID: 32615994
[TBL] [Abstract][Full Text] [Related]
7. Inhaled recombinant GM-CSF reduces the need for whole lung lavage and improves gas exchange in autoimmune pulmonary alveolar proteinosis patients.
Campo I; Carey BC; Paracchini E; Kadija Z; De Silvestri A; Rodi G; De Amici M; Torre C; Zorzetto M; Griese M; Meloni F; Corsico AG; Trapnell BC; Mariani F
Eur Respir J; 2024 Jan; 63(1):. PubMed ID: 37973175
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis.
Seymour JF; Presneill JJ; Schoch OD; Downie GH; Moore PE; Doyle IR; Vincent JM; Nakata K; Kitamura T; Langton D; Pain MC; Dunn AR
Am J Respir Crit Care Med; 2001 Feb; 163(2):524-31. PubMed ID: 11179134
[TBL] [Abstract][Full Text] [Related]
9. Bilateral peripheral infiltrates refractory to immunosuppressants were diagnosed as autoimmune pulmonary alveolar proteinosis and improved by inhalation of granulocyte/macrophage-colony stimulating factor.
Satoh H; Tazawa R; Sakakibara T; Ohkouchi S; Ebina M; Miki M; Nakata K; Nukiwa T
Intern Med; 2012; 51(13):1737-42. PubMed ID: 22790136
[TBL] [Abstract][Full Text] [Related]
10. Serum neutralizing capacity of GM-CSF reflects disease severity in a patient with pulmonary alveolar proteinosis successfully treated with inhaled GM-CSF.
Arai T; Hamano E; Inoue Y; Ryushi T; Nukiwa T; Sakatani M; Nakata K
Respir Med; 2004 Dec; 98(12):1227-30. PubMed ID: 15588045
[TBL] [Abstract][Full Text] [Related]
11. Better approach for autoimmune pulmonary alveolar proteinosis treatment: inhaled or subcutaneous granulocyte-macrophage colony-stimulating factor: a meta-analyses.
Sheng G; Chen P; Wei Y; Chu J; Cao X; Zhang HL
Respir Res; 2018 Aug; 19(1):163. PubMed ID: 30165864
[TBL] [Abstract][Full Text] [Related]
12. An open-label trial of rituximab therapy in pulmonary alveolar proteinosis.
Kavuru MS; Malur A; Marshall I; Barna BP; Meziane M; Huizar I; Dalrymple H; Karnekar R; Thomassen MJ
Eur Respir J; 2011 Dec; 38(6):1361-7. PubMed ID: 21478218
[TBL] [Abstract][Full Text] [Related]
13. Nebulised granulocyte-macrophage colony-stimulating factor (GM-CSF) in autoimmune pulmonary alveolar proteinosis: a systematic review and meta-analysis.
Munsif M; Sweeney D; Leong TL; Stirling RG
Eur Respir Rev; 2023 Dec; 32(170):. PubMed ID: 37993127
[TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapy options in pulmonary alveolar proteinosis.
Antoniu SA; Rajnoveanu R; Grigore M; Antohe I
Expert Opin Pharmacother; 2020 Aug; 21(11):1359-1366. PubMed ID: 32511020
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of granulocyte-macrophage colony-stimulating factor therapy in autoimmune pulmonary alveolar proteinosis: a meta-analysis of observational studies.
Khan A; Agarwal R; Aggarwal AN
Chest; 2012 May; 141(5):1273-1283. PubMed ID: 22016491
[TBL] [Abstract][Full Text] [Related]
16. [Response to inhaled granulocyte-macrophage colony-stimulating factor in a patient with alveolar proteinosis].
Rodríguez Portal JA; Rodríguez Becerra E; Sánchez Garrido A
Arch Bronconeumol; 2009 Mar; 45(3):150-2. PubMed ID: 19286115
[TBL] [Abstract][Full Text] [Related]
17. Response to inhaled granulocyte-macrophage colony-stimulating factor in patient with mild-to-moderate autoimmune pulmonary alveolar proteinosis-24 months of follow-up.
Oterino-Moreira I; Linares-Asensio MJ; Sanz-Márquez S; Pérez-Encinas M
Clin Respir J; 2023 Oct; 17(10):1077-1081. PubMed ID: 37300395
[TBL] [Abstract][Full Text] [Related]
18. An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis.
Venkateshiah SB; Yan TD; Bonfield TL; Thomassen MJ; Meziane M; Czich C; Kavuru MS
Chest; 2006 Jul; 130(1):227-37. PubMed ID: 16840407
[TBL] [Abstract][Full Text] [Related]
19. Granulocyte-macrophage colony-stimulating factor and lung immunity in pulmonary alveolar proteinosis.
Tazawa R; Hamano E; Arai T; Ohta H; Ishimoto O; Uchida K; Watanabe M; Saito J; Takeshita M; Hirabayashi Y; Ishige I; Eishi Y; Hagiwara K; Ebina M; Inoue Y; Nakata K; Nukiwa T
Am J Respir Crit Care Med; 2005 May; 171(10):1142-9. PubMed ID: 15735059
[TBL] [Abstract][Full Text] [Related]
20. GM-CSF pathway correction in pulmonary alveolar proteinosis.
Antoniu SA
Expert Opin Biol Ther; 2010 Sep; 10(9):1357-65. PubMed ID: 20695835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
